ACN9 Activators
ACN9 Activators encompass a range of chemical compounds primarily affecting cyclic nucleotide levels and protein phosphorylation states, which can lead to the enhancement of ACN9's functional activity. Forskolin and Isoproterenol, through their action on adenylyl cyclase, elevate intracellular cAMP levels, potentially enhancing cAMP-dependent processes that ACN9 is part of. Similarly, IBMX, Cilostamide, Ro 20-1724, Anagrelide, and Rolipram function as phosphodiesterase inhibitors, preventing the breakdown of cAMP and in some cases cGMP, which may lead to the indirect activation of ACN9 via these cyclic nucleotide signaling pathways. Zaprinast, as a specific PDE5 inhibitor, increases cGMP levels and might alsoI apologize for the interruption in the previous response. Let's continue with the second paragraph for Question 2.
Zaprinast, as a specific PDE5 inhibitor, increases cGMP levels and might also contribute to the enhancement of ACN9 activity if this protein is involved in cGMP-dependent signaling. Paclitaxel and Vincristine, by targeting microtubules, could alter cellular dynamics and signaling pathways that potentially engage ACN9, thereby indirectly leading to its activation. Okadaic acid, by inhibiting protein phosphatases, may increase the phosphorylation of proteins within ACN9-associated pathways, indirectly enhancing the protein's activity. Finally, Phorbol 12-myristate 13-acetate (PMA) is a well-known activator of protein kinase C (PKC), which could lead to the enhancement of ACN9 activity if ACN9 is a participant in PKC-mediated cellular processes. These chemical activators, by influencing specific biochemical pathways and cellular processes, have the capacity to enhance the functional activity of ACN9 without the need for direct interaction or upregulation of the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a labdane diterpenoid that activates the enzyme adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP) in cells. Elevated cAMP levels can promote the activation of various cAMP-dependent pathways, which may include the enhancement of ACN9 activity if ACN9 is involved in such pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX (3-Isobutyl-1-methylxanthine) is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels in cells. This elevation in cyclic nucleotides may indirectly enhance ACN9 activity by stimulating cAMP or cGMP-dependent signaling processes that ACN9 is a part of. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3 (PDE3) that results in the accumulation of cAMP within the cell. This increased level of cAMP might enhance ACN9 activity by activating cAMP-dependent signaling cascades that involve ACN9. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine and beta-adrenergic agonist that leads to the activation of adenylyl cyclase and increased production of cAMP. The downstream effects of cAMP may include the activation of ACN9 through cAMP-dependent signaling pathways. | ||||||
Ro 20-1724 | 29925-17-5 | sc-200709 sc-200709A sc-200709B | 100 mg 1 g 5 g | $87.00 $426.00 $1574.00 | 17 | |
Ro 20-1724 is a selective inhibitor of PDE4, which increases intracellular cAMP levels, potentially enhancing ACN9 activity by activating cAMP-dependent protein kinases that interact with ACN9. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of PDE5, which increases cGMP levels, and may indirectly enhance ACN9 activity through cGMP-dependent signaling pathways that ACN9 is involved in. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is a PDE3 inhibitor that elevates cAMP levels and could enhance ACN9 activity by modulating cAMP-dependent signaling pathways, provided ACN9 functions within these pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a PDE4 inhibitor that increases cAMP levels and could indirectly increase ACN9 activity through the activation of cAMP-dependent signaling mechanisms that include ACN9. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel is a chemotherapeutic agent that stabilizes microtubules and could indirectly enhance ACN9 activity if ACN9 is involved in signaling pathways that are affected by microtubule dynamics. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation of various proteins. If ACN9 function is modulated by phosphorylation, okadaic acid may enhance ACN9 activity by affecting the phosphorylation state of proteins within ACN9-associated pathways. | ||||||